These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 12458647)
41. Pharmacotherapy for obesity--promise and uncertainty. Yanovski SZ N Engl J Med; 2005 Nov; 353(20):2187-9. PubMed ID: 16291989 [No Abstract] [Full Text] [Related]
42. Pharmacologic agents for the treatment of obesity. Mathys M Clin Geriatr Med; 2005 Nov; 21(4):735-46, vii. PubMed ID: 16182086 [TBL] [Abstract][Full Text] [Related]
43. The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort. Douglas IJ; Bhaskaran K; Batterham RL; Smeeth L Br J Clin Pharmacol; 2015 Jun; 79(6):1020-7. PubMed ID: 25641659 [TBL] [Abstract][Full Text] [Related]
44. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442 [TBL] [Abstract][Full Text] [Related]
45. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents. García Díaz E; Martín Folgueras T Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560 [TBL] [Abstract][Full Text] [Related]
47. [Weight loss via drug therapy]. Wirth A Internist (Berl); 2003 Mar; 44(3):359-62, 363-6. PubMed ID: 12731423 [TBL] [Abstract][Full Text] [Related]
48. Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance. Gursoy A; Erdogan MF; Cin MO; Cesur M; Baskal N Eat Weight Disord; 2006 Dec; 11(4):e127-32. PubMed ID: 17272944 [TBL] [Abstract][Full Text] [Related]
49. New drug policy in childhood obesity. Molnár D Int J Obes (Lond); 2005 Sep; 29 Suppl 2():S62-5. PubMed ID: 16385755 [TBL] [Abstract][Full Text] [Related]
51. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Sari R; Balci MK; Cakir M; Altunbas H; Karayalcin U Endocr Res; 2004 May; 30(2):159-67. PubMed ID: 15473126 [TBL] [Abstract][Full Text] [Related]
52. Pharmacotherapy of obesity. Finer N Best Pract Res Clin Endocrinol Metab; 2002 Dec; 16(4):717-42. PubMed ID: 12468417 [TBL] [Abstract][Full Text] [Related]
53. What role for weight-loss medication? Weighing the pros and cons for obese patients. Wyatt HR; Hill JO Postgrad Med; 2004 Jan; 115(1):38-40, 43-5, 58. PubMed ID: 14755876 [TBL] [Abstract][Full Text] [Related]
54. [Pharmacotherapy of obesity]. Tripp B; Ludvik B Wien Med Wochenschr; 2004 Jul; 154(13-14):320-8. PubMed ID: 15368953 [TBL] [Abstract][Full Text] [Related]
55. Current pharmacological approaches to the treatment of obesity. Hauner H Int J Obes Relat Metab Disord; 2001 May; 25 Suppl 1():S102-6. PubMed ID: 11466601 [TBL] [Abstract][Full Text] [Related]
56. [Perspective of obesity pharmacotherapy]. Svačina S; Sucharda P; Stránská Z; Matoulek M Cas Lek Cesk; 2014; 153(3):127-30. PubMed ID: 24968289 [TBL] [Abstract][Full Text] [Related]
58. Implementing antiobesity treatment in a patient with a mood disorder. Taylor VH J Psychiatry Neurosci; 2008 Nov; 33(6):E1-2. PubMed ID: 18982178 [No Abstract] [Full Text] [Related]
59. Currently available drugs for the treatment of obesity: Sibutramine and orlistat. Chaput JP; St-Pierre S; Tremblay A Mini Rev Med Chem; 2007 Jan; 7(1):3-10. PubMed ID: 17266632 [TBL] [Abstract][Full Text] [Related]